BioDelivery Sciences International Inc. is set to receive $30 million in an up-front payment from Swedish specialty pharma Meda AB under a licensing agreement for BEMA Fentanyl, a dissolvable opioid disc product. (BioWorld Today)
BioDelivery Sciences International Inc. is set to receive $30 million in an up-front payment from Swedish specialty pharma Meda AB under a licensing agreement for BEMA Fentanyl, a dissolvable opioid disc product. (BioWorld Today)